Life science technology company PacBio (NASDAQ:PACB), a developer of advanced sequencing solutions, and microbiome research and discovery specialist Intus Bio announced on Friday the launch of GutID, the first commercial human gut health test powered by PacBio's HiFi sequencing technology and Intus Bio's Titan-1 platform.
GutID is designed to provide a comprehensive and accurate analysis of the gut microbiome, including strain-level identification of both beneficial and pathogenic bacteria.
The test utilises PacBio's long-read sequencing technology, enabling high-resolution analysis of the microbiome and delivering robust and repeatable results.
GutID is targeted at individuals seeking to understand and improve their gut health, and is particularly beneficial for those with conditions such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).
The test involves a simple at-home sample collection and provides users with a detailed report, including a microbiome health score and personalised recommendations.
GRIN Therapeutics' radiprodil granted Priority Medicine designation in Europe
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100
Yingli Pharma's linperlisib Phase 3 registration study approved by US FDA
Oncopeptides secures FDA approval to resume OPD5 clinical development
Spinogenix starts enrolment for SPG302 Phase 2 trial in schizophrenia
CRISM Therapeutics advances clinical trial for ChemoSeed
Eli Lilly reveals positive Phase two results for lepodisiran
Dupixent receives approval in Japan as first biologic for COPD treatment
Alys Pharmaceuticals doses first patient in Phase IIa trial of ALY-101
Spyre Therapeutics starts dosing in Phase 1 clinical trial of SPY003
IASO Biotherapeutics receives Macau approval for equecabtagene autoleucel NDA
Alzinova AB reports positive final Phase 1b results for ALZ-101 in Alzheimer's
Primrose Bio launches Prima RNApols ExTend RNA polymerase for long-template mRNA manufacturing